Seroprevalence Study and Cross-Sectional Survey on COVID-19 for a Plan to Reopen the University of Alicante (Spain)
Por:
Tuells J, Egoavil CM, Pena Pardo MA, Montagud AC, Montagud E, Caballero P, Zapater P, Puig-Barberá J and Hurtado-Sanchez JA
Publicada:
1 feb 2021
Ahead of Print:
16 feb 2021
Resumen:
The implementation of strategies to mitigate possible cases of COVID-19 were addressed at the University of Alicante for the safe reopening of the 2020/2021 academic year. To discover the prevalence of immunity against SARS-CoV-2, a study was designed using a rapid immunoassay test (carried out between 6 and 22 July 2020), and in addition a cross-sectional survey was conducted on risk factors, symptoms, predisposition for becoming vaccinated, and sources of information about COVID-19. A random sample, stratified by students, faculty, and administrative staff, was selected. The seroprevalence found was 2.64% (39/1479; 95% CI 1.8-3.4), and the adjusted seroprevalence was 2.89% (95% CI 2.1-3.7). The average age of the students was 23.2 years old, and 47.6 years old for staff. In relation to COVID-19, the following was found: 17.7% pauci-symptomatic, 1.3% symptomatic, 5.5% contact with cases, 4.9% confined, and 0.3% PCR positive. More than 90% complied with preventive measures. The proportion willing to receive the COVID-19 vaccine was 91%. Their sources of information were the Internet (74%) and television (70.1%). They requested that the university offer information (45.1%), training (27%), and provide Personal Protective Equipment (PPE) (26.3%). Lastly, 87.9% would repeat the test. A plan was established that included the follow-up of cases and contacts, random sample testing, training courses, bimodal teaching, a specific website, and the distribution of PPE.
Filiaciones:
:
Department of Community Nursing, Preventive Medicine, Public Health and History of Science, University of Alicante, 03690 Alicante, Spain
Egoavil CM:
Clinical Pharmacology Unit, General University Hospital of Alicante, Institute for Health and Biomedical Research (ISABIAL Foundation), C/Pintor Baeza, 12, 03010 Alicante, Spain
Pena Pardo MA:
Clinical Pharmacology Unit, General University Hospital of Alicante, Institute for Health and Biomedical Research (ISABIAL Foundation), C/Pintor Baeza, 12, 03010 Alicante, Spain
Montagud AC:
Immunology Department, Fundación Jiménez Díaz University Hospital, 28040 Madrid, Spain
Montagud E:
Primary Care Pharmacy Service, University Hospital of Torrevieja, 03186 Torrevieja, Alicante, Spain
Caballero P:
Department of Community Nursing, Preventive Medicine, Public Health and History of Science, University of Alicante, 03690 Alicante, Spain
Zapater P:
Clinical Pharmacology Unit, General University Hospital of Alicante, Institute for Health and Biomedical Research (ISABIAL Foundation), C/Pintor Baeza, 12, 03010 Alicante, Spain
:
Vaccines Research Area FISABIO, 46020 Valencia, Spain
Hurtado-Sanchez JA:
Faculty of Health Sciences, University of Alicante, 03690 Alicante, Spain
gold, Green Published
|